Skip to main content
TipRanks
Go Ultimate75% OFF

Vincent Medical Holdings Limited (1612) AI Stock Analysis

1 Followers
HK:1612

Vincent Medical Holdings Limited

(HKEX:1612)

Select Model
Rating:71.1Outperform
Price Target:HKD 0.79▲(12.95% Upside)
Action:reiterated
Date:08/19/26

The stock earns a moderately strong score driven primarily by a solid financial profile, with profitability and margins rebounding and a conservative balance sheet, while an undemanding valuation with a low P/E and high dividend yield further supports the rating. These positives are tempered by a history of cyclical revenue and earnings and uneven free cash flow, alongside neutral-to-soft technicals that show limited current price momentum, keeping the score below the top tier.

Positive Factors
Revenue and Margin RecoveryThe return to multi-year revenue growth, combined with materially higher gross and net margins in 2025, indicates improving operating performance. If this recovery persists, it can strengthen internal funding capacity and support a more durable earnings base over the next several quarters.
Negative Factors
Weak Free Cash Flow ConversionLow conversion of reported profit into free cash flow means earnings quality remains weaker than the income statement alone suggests. Persistent conversion pressure could limit internally funded expansion and shareholder returns, while making cash generation more sensitive to operating and investment requirements.

Vincent Medical Holdings Limited (1612) vs. iShares MSCI Hong Kong ETF (EWH)

-20%-10%0%10%20%30%HK:1612-12.03%EWH+8.92%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 442.07M
Dividend Yield
6.76%
Average Volume (3M)
165.16K
Price to Earnings (P/E)
4.6
Beta (1Y)
0.78
Revenue Growth
10.95%
EPS Growth
9.26%
Country
Hong Kong
Employees
1,556
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Vincent Medical Holdings Limited Business Overview & Revenue Model

Company Description

Vincent Medical Holdings Limited is an investment holding company engaged in the comprehensive process of designing, manufacturing, marketing, and distributing medical devices. Its operations are bifurcated into two main business models: providing pr...

Vincent Medical Holdings Limited Financial Statement Overview

Summary

Score reflects recovered profitability with low double-digit margins, a conservatively financed balance sheet with growing equity and moderate debt, offset by cyclical revenue and earnings and volatile free cash flow that weakens cash conversion.

Income Statement

72Positive

Balance Sheet

80Positive

Cash Flow

58Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue964.90M932.78M800.96M717.97M629.24M777.72M
Gross Profit333.74M327.44M259.99M240.39M147.83M243.83M
EBITDA164.90M170.76M114.39M104.11M29.95M114.55M
Net Income96.30M104.38M69.17M57.27M-17.40M60.70M
Balance Sheet
Total Assets1.27B1.17B919.68M786.61M726.70M846.15M
Cash, Cash Equivalents and Short-Term Investments199.93M250.87M173.44M175.78M159.34M173.17M
Total Debt240.66M177.42M99.65M37.38M60.39M62.96M
Total Liabilities546.08M498.33M336.33M243.52M228.09M245.72M
Stockholders Equity715.77M664.65M578.55M541.84M498.01M598.36M
Cash Flow
Free Cash Flow-25.52M54.64M-26.52M61.28M57.67M94.48M
Operating Cash Flow59.99M168.42M73.48M124.97M76.27M119.43M
Investing Cash Flow-86.77M-119.77M-98.81M-62.37M-18.61M-20.69M
Financing Cash Flow20.84M27.34M26.39M-45.37M-67.84M-101.16M

Vincent Medical Holdings Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price0.69

Price Trends

50DMA0.69Negative
100DMA0.69Negative
200DMA0.78Negative

Market Momentum

MACD-0.00Positive
RSI40.95Neutral
STOCH25.93Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1612, the sentiment is Negative. The current price of 0.69 is below the 20-day moving average (MA) of 0.70, above the 50-day MA of 0.69, and below the 200-day MA of 0.78, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 40.95 is Neutral, neither overbought nor oversold. The STOCH value of 25.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1612.

Vincent Medical Holdings Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:1612 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:1789HK:178977OutperformHKD 5.21B11.7513.24%2.51%16.15%31.89%
HK:1858HK:185872OutperformHKD 5.12B18.648.83%5.53%-9.00%10.62%
HK:1612HK:161271OutperformHKD 448.87M4.5713.95%6.76%10.95%9.26%
HK:2172HK:217265NeutralHKD 4.71B21.3410.38%1.74%3.83%-27.04%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:6669HK:666951NeutralHKD 1.44B-24.53-3.50%―9.36%-153.54%
HK:9996HK:999645NeutralHKD 2.59B-15.41-7.65%―21.23%36.89%

* Healthcare Sector Average

Performance Comparison

-60%-40%-20%0%20%HK:1612HK:9996HK:6669HK:1789HK:1858HK:2172Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:1612 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:1612Vincent Medical Holdings Limited0.69-0.09-11.01%
HK:9996Peijia Medical Ltd.3.65-1.99-35.28%
HK:6669Acotec Scientific Holdings Limited4.49-8.43-65.26%
HK:1789AK Medical Holdings Ltd.4.72-0.93-16.50%
HK:1858Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H7.20-10.25-58.75%
HK:2172MicroPort NeuroTech Limited8.05-2.88-26.31%

Vincent Medical Holdings Limited Corporate Events

Vincent Medical Grows Revenue as New China Plant Weighs on Profit

Aug 25, 2026

Vincent Medical Holdings reported a 7.1% year-on-year rise in revenue to HK$481.6 million for the six months ended 30 June 2026, driven mainly by a 7.2% increase in its imaging disposable products segment to HK$261.6 million. Despite higher raw mater...

Vincent Medical Declares Interim HKD0.02 Dividend for First Half of 2026

Aug 25, 2026

Vincent Medical Holdings Limited has announced an interim ordinary cash dividend of HKD 0.02 per share for the six months ended 30 June 2026, for the financial year ending 31 December 2026. The dividend reflects the board’s decision to return cash to...

Vincent Medical strengthens board with new independent director

Aug 25, 2026

Vincent Medical Holdings Limited has appointed Ms. Liu Yin Yan Elizabeth as an independent non-executive director, effective 26 August 2026, strengthening its board with extensive Hong Kong legal and capital markets experience. Liu, a qualified solic...

Vincent Medical Clarifies Board and Committee Structure Effective August 2026

Aug 25, 2026

Vincent Medical Holdings Limited has updated its board composition, confirming a mix of executive, non-executive and independent non-executive directors effective 26 August 2026. The chairman role is held by Mr. Choi Man Shing, while Mr. Choi Cheung...

Vincent Medical Sets August Board Meeting to Approve Interim Results and Dividend

Aug 11, 2026

Vincent Medical Holdings Limited has scheduled a board meeting for 25 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The board will also consider the publication of these interim results and evaluate the...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026